NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Price, News & Analysis $2.73 +0.06 (+2.25%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Anixa Biosciences Stock (NASDAQ:ANIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Anixa Biosciences alerts:Sign Up Key Stats Today's Range$2.65▼$2.7950-Day Range$2.50▼$3.1452-Week Range$2.44▼$5.46Volume114,297 shsAverage Volume120,494 shsMarket Capitalization$91.54 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingHold Company Overview Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors. In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom. ADAPT is designed to generate biomarker signatures for early detection and monitoring of cancer and other diseases, with initial studies focusing on breast and ovarian malignancies. This platform seeks to deliver non-invasive, blood-based tests that can aid in disease stratification and treatment decisions. Since its founding, Anixa has engaged with academic institutions, government agencies and strategic partners to support its preclinical and clinical programs. The firm has leveraged grants and collaborations to advance its SARS-CoV-2 vaccine into regulatory review and to expand its oncology candidates into Phase II development. Headquartered in San Jose, California, Anixa maintains operations across the United States and continues to establish partnerships to extend its global research footprint. Under the leadership of a management team with extensive experience in biotechnology, oncology and vaccine development, Anixa Biosciences is focused on translating its innovative platforms into clinically meaningful products. The company’s multidisciplinary approach, encompassing both therapeutic and diagnostic divisions, aims to address unmet needs in cancer and infectious disease through precision immunology solutions.AI Generated. May Contain Errors. Read More Anixa Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreANIX MarketRank™: Anixa Biosciences scored higher than 37% of companies evaluated by MarketBeat, and ranked 684th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingAnixa Biosciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAnixa Biosciences has a consensus price target of $8.50, representing about 211.4% upside from its current price of $2.73.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Anixa Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -8.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -8.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 6.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anixa Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.20% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 8.47.Change versus previous monthShort interest in Anixa Biosciences has recently decreased by 0.67%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Anixa Biosciences this week, compared to 3 articles on an average week.Search Interest14 people have searched for ANIX on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows4 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders26.40% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions29.13% of the stock of Anixa Biosciences is held by institutions.Read more about Anixa Biosciences' insider trading history. Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIX Stock News HeadlinesAnixa Biosciences (ANIX) to Release Earnings on WednesdayMay 20 at 2:15 AM | americanbankingnews.com/C O R R E C T I O N -- Anixa Biosciences, Inc./May 13, 2026 | finance.yahoo.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.May 20 at 1:00 AM | Reagan Gold Group (Ad)Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T TherapyMay 11, 2026 | prnewswire.comAnixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TVMay 1, 2026 | prnewswire.comAnixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine TechnologyApril 29, 2026 | prnewswire.comAnixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual MeetingApril 22, 2026 | prnewswire.comAnixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026April 9, 2026 | prnewswire.comSee More Headlines ANIX Stock Analysis - Frequently Asked Questions How have ANIX shares performed this year? Anixa Biosciences' stock was trading at $3.12 at the start of the year. Since then, ANIX stock has decreased by 12.5% and is now trading at $2.73. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences Inc (NASDAQ:ANIX) issued its quarterly earnings data on Monday, March, 9th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. Who are Anixa Biosciences' major shareholders? Top institutional investors of Anixa Biosciences include Renaissance Technologies LLC (0.18%), Kestra Advisory Services LLC (0.15%) and Bank of New York Mellon Corp (0.14%). Insiders that own company stock include Lewis H Titterton Jr, Amit Kumar, Arnold M Baskies and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anixa Biosciences investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Coty (COTY), AbbVie (ABBV), Adverum Biotechnologies (ADVM) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings3/09/2026Today5/20/2026Next Earnings (Estimated)5/27/2026Fiscal Year End10/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ANIX's financial health is in the Yellow zone, according to TradeSmith. ANIX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIX CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees5Year Founded1982Price Target and Rating Average Price Target for Anixa Biosciences$8.50 High Price Target$10.00 Low Price Target$7.00 Potential Upside/Downside+211.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.95% Return on Assets-62.53% Debt Debt-to-Equity RatioN/A Current Ratio12.18 Quick Ratio12.18 Sales & Book Value Annual Sales$210 thousand Price / Sales435.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book6.50Miscellaneous Outstanding Shares33,530,000Free Float24,677,000Market Cap$91.54 million OptionableOptionable Beta0.64 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ANIX) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredMusk's acquisition pattern points to ONE stockMusk needed solar - he acquired SolarCity. Needed data - he bought Twitter. The pattern is clear: when a suppl...Behind the Markets | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe filing was one thing. June 1 is another.The SpaceX filing got attention - but according to macroeconomic strategist Dr. Mark Skousen of The Oxford Clu...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
